Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cancer vaccines.

Igor Espinoza-Delgado1

  • 1Section of Hematology-Oncology, Gerontology Research Center, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224, USA. espinozaig@grc.nia.nih.gov

The Oncologist
|August 8, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Toxicities of Histone Deacetylase Inhibitors.

Pharmaceuticals (Basel, Switzerland)·2016
Same author

Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies.

Leukemia research·2016
Same author

A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia.

Leukemia & lymphoma·2015
Same author

A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.

Investigational new drugs·2013
Same author

A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors.

Investigational new drugs·2013
Same author

Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes.

Cancer chemotherapy and pharmacology·2013

Cancer vaccines show promise in stimulating tumor-specific immune responses, with early trials indicating clinical benefits. Future research will focus on optimizing immune cell interactions and patient selection for effective cancer immunotherapy.

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Cancer immunotherapy, initiated over a century ago, is evolving with recent advances in immunology.
  • Understanding tumor-immune system interactions is key, as they can lead to either antitumor responses or immune tolerance.

Purpose of the Study:

  • To discuss the significant interest in cancer vaccines.
  • To explore their potential for inducing in vivo antitumor responses.

Main Methods:

  • Review of preclinical models and early human clinical trials.
  • Analysis of immune response induction and clinical outcomes.

Main Results:

  • Cancer vaccines have demonstrated the ability to elicit tumor-specific immune responses.

Related Experiment Videos

  • Some trials show a correlation between these responses and clinical benefits.

    • Conclusions:

    • Cancer vaccines hold potential for cancer immunotherapy.
    • Future challenges include optimizing immune cell interactions and developing patient monitoring strategies for personalized treatment.